Examining Neuroinflammation in AlzHeimer's
- Conditions
- Alzheimer Disease, Early-Onset
- Registration Number
- NCT03548883
- Lead Sponsor
- AdventHealth
- Brief Summary
Alzheimer disease (AD) is a neurodegenerative disorder with a poorly understood pathology. It is an irreversible progressive brain disease that slowly deteriorates memory, thinking and behavior. It affects the elderly population and is also hereditary. The incidence doubles with every decade after sixty with no signs of leveling off. More than 35 million people Worldwide, including 5.5 million living in the United States, suffer from AD. As the United States population ages, it is expected that the number of people with AD will increase, reaching 13.2 to 16.0 million by the year 2050. The cost of care for patients with AD in the United States is expected to rise as well, from $172 billion a year in 2010 to a trillion dollars a year by 2050.
Although the exact etiopathology is not known there are several lines of evidence that suggest that metabolic and inflammatory features are important. It also has been known for many years that the Blood Brain Barrier (BBB) of Alzheimer's patients allow more harmful particles to cross into the brain than the BBBs of those without the disease do. It's known that this barrier, which is regulating transfer of molecules between the brain and blood, and vice versa blood and brain, can become leaky and dysfunctional (in particular capillaries dysfunction) and lead to subsequent problems likely contributing to onset and progression of dementia. This protocol will explore several of the most promising putative factors that cause AD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gender Two years (Male or Female)
Adiponectin Two years Measured of adiponectin level in the blood
Height Two years Measured in meters
Lipid profile Two years Measured of the HDL, LDL and VLDL content in the blood (measured in mg/dL)
Compare the Blood Brain Barrier leaking between AD, T2D and healthy control subjects. Two years A MRI of the brain with contrast will be used to assess the permeability of the Blood Brain Barrier.
Age Two years Measured in years
BMI Two years will be determined by dividing weight by height (square)
Body composition Two years Measured by Dexascan
Weight Two years Measured in kilograms
Race Two years White/Black or African American/Asian/Other/Unknown or not reported
Insulin Two years Measured of insulin level in the blood
Cognitive data Two years Evaluated by the Geriatric Depression Scale (GDS)
Free Fatty Acid Two years Measured of free fatty acid level in the blood
Transcriptomic profiles of the cells isolated from the blood Two years after isolation of the peripheral blood mononuclear cell (PBMC) from the blood, measure of gene expression by RT-qPCR (real time quantitative polymerase chain reaction)
Activity monitoring - lying down time Two years measured by wearing an arm band - measured in minutes
Activity monitoring - energy cost of free-living activity Two years measured by wearing an arm band - measured in minutes
Epigenetic Two years after isolation of the PBMC from the blood measure of DNA methylation
Proteomic of the cells isolated from the blood Two years after isolation of the PBMC from the blood, measure of proteins by western blot
Metabolic of the cells isolated from the blood Two years after isolation of the PBMC from the blood measure of metabolites by MS
Activity monitoring - sleeping time Two years measured by wearing an arm band - measured in minutes
- Secondary Outcome Measures
Name Time Method